Solicep (solifenacin succinate): Uses, Dosage & Side Effects

What it's for (Indications)

Solifenacin succinate is indicated for the treatment of overactive bladder with symptoms of urinary urgency, increased frequency of urination, and urge incontinence.

Dosage Information

Type	Guideline
Standard	The recommended once-daily dose of solifenacin succinate (for pediatric patients aged 2 years and older) is based on patient weight. Dosing should be initiated at the recommended starting dose and may be titrated to the lowest effective dose, but should not exceed the maximum recommended dose. The oral suspension should be taken orally followed by liquid (e.g., water or milk). Do not exceed the recommended starting dose in patients with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m^2), moderate hepatic impairment (Child-Pugh B), or when concomitantly used with strong CYP3A4 inhibitors. Solifenacin succinate is not recommended in patients with severe hepatic impairment (Child-Pugh C).

Type

Guideline

Standard

The recommended once-daily dose of solifenacin succinate (for pediatric patients aged 2 years and older) is based on patient weight. Dosing should be initiated at the recommended starting dose and may be titrated to the lowest effective dose, but should not exceed the maximum recommended dose. The oral suspension should be taken orally followed by liquid (e.g., water or milk). Do not exceed the recommended starting dose in patients with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m^2), moderate hepatic impairment (Child-Pugh B), or when concomitantly used with strong CYP3A4 inhibitors. Solifenacin succinate is not recommended in patients with severe hepatic impairment (Child-Pugh C).

Safety & Warnings

Common Side Effects

Common adverse reactions include dry mouth, constipation, and urinary tract infection.
Other reported side effects include stomach pain, upset stomach, vomiting, heartburn, dry eyes, blurred vision, and dry skin.
Serious adverse reactions can include angioedema, anaphylactic reactions, urinary retention, gastrointestinal disorders, central nervous system effects, and QT prolongation (especially in patients at high risk).

Serious Warnings

Black Box Warning: None
Exercise caution when prescribing to pregnant females as the effect is undetermined.
The use of solifenacin succinate should be avoided in lactating females.
Patients should not drive or operate machinery immediately after taking this medicine due to potential dizziness or drowsiness.
Avoid consuming alcohol with solifenacin due to potential for extreme dizziness.
Other causes of frequent urination should be thoroughly assessed before starting treatment.
Use with caution in patients with clinically significant bladder outflow obstruction (at risk of urinary retention), gastrointestinal obstructive disorders, or risk of decreased gastrointestinal motility.
Exercise caution in patients with severe renal impairment (creatinine clearance < 30 mL/min/1.
73 m^2) and moderate hepatic impairment (Child-Pugh B).
Caution is advised with concomitant use of a potent CYP3A4 inhibitor.
Use with caution in patients with hiatus hernia, gastroesophageal reflux disease, people taking bisphosphonates, and patients with autonomic neuropathy.
Provide a complete medical history to your doctor, especially concerning liver and kidney disease, myasthenia gravis, narrow-angle glaucoma, gastric retention, prolonged QT interval, ulcerative colitis, and benign prostatic hypertrophy.
Inform your doctor about all prescription and nonprescription medicines you are taking.
Discuss drinking grapefruit juice with your doctor while on this medication.
Monitor for potential angioedema, anaphylactic reactions, urinary retention, gastrointestinal disorders, central nervous system effects, and QT prolongation.

How it Works (Mechanism of Action)

Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle.